Records containing: Non Small Cell Lung Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2023-02-08
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Gefitinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
CLINICAL_TRIALS study record update · 2023-01-26
A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC
CLINICAL_TRIALS study record update · 2023-01-20
A Phase III Randomized, Controlled, Double-Blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of HS-10296 Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Sensitizing Mutations
CLINICAL_TRIALS study record update · 2023-01-12
A Prospective, Randomized, Single-Blind, Active Control Trial to Compare Safety and Effectiveness Of Liposomal Bupivacaine (Exparel) to Standard Bupivacaine HCl (Marcaine) for Pain Management in Patients Undergoing Video-Assisted Thoracoscopic Lobectomy
CLINICAL_TRIALS study record update · 2023-01-06
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2023-01-06
Real World Effectiveness of Capmatinib in Patients With Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
CLINICAL_TRIALS study record update · 2023-01-06
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (Secondary Data Use Study of Dabrafenib-Trametinib in "Real Life" for Non-Small Cell Lung Cancer With a BRAF V600 Mutation)
CLINICAL_TRIALS study record update · 2022-12-09
A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2022-12-05
Real-world Analysis of Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable Non-small Cell Lung Cancer
CLINICAL_TRIALS study record update · 2022-11-28
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
CLINICAL_TRIALS study record update · 2022-11-25
A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases
CLINICAL_TRIALS study record update · 2022-11-17
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
CLINICAL_TRIALS study record update · 2022-11-14
An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen
CLINICAL_TRIALS study record update · 2022-10-20
Dose-escalation by Hypofractionated Stereotactic Radiotherapy Simultaneous Integrated Boost IMRT for Brain Metastases in Non Small Cell Lung Cancer：A Phase I Study
CLINICAL_TRIALS study record update · 2022-10-10
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
CLINICAL_TRIALS study record update · 2022-09-29
Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study
CLINICAL_TRIALS study record update · 2022-09-28
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
CLINICAL_TRIALS study record update · 2022-09-26
Pharmacokinetic Boosting of Osimertinib in Patients With Non-small Cell Lung Cancer.
CLINICAL_TRIALS study record update · 2022-09-15
Phase I Trial Evaluating Stereotactic Body Radiotherapy (SBRT) Dose Escalation for Reirradiation of Inoperable Lung Lesions
CLINICAL_TRIALS study record update · 2022-09-14
A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.
CLINICAL_TRIALS study record update · 2022-09-10
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer
CLINICAL_TRIALS study record update · 2022-09-08
A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects With Previously Treated Cancers
CLINICAL_TRIALS study record update · 2022-08-24
Phase II Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib and Adjuvant Pembrolizumab in Patients With Surgically Resectable Non-Small- Cell Lung Cancer (NSCLC)
CLINICAL_TRIALS study record update · 2022-08-19
Phase I Study of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.
CLINICAL_TRIALS study record update · 2022-08-18
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer